Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 12/20 | 0.41 |
| ▸ | THRA | P10827 | 4/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10394517 | 0.90 | MEN1 (0.64) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL5561466 | 0.88 | MEN1 (0.54) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL6345637 | 0.86 | MEN1 (0.65) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL9823772 | 0.86 | MEN1 (0.65) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL8232445 | 0.86 | MEN1 (0.60) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL5566019 | 0.85 | MEN1 (0.64) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL10394519 | 0.85 | MEN1 (0.64) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL5566328 | 0.85 | MEN1 (0.61) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL5566256 | 0.85 | MEN1 (0.48) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL10394521 | 0.83 | MEN1 (0.61) | MEN1NR1I2KMT2ATHRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000040-B1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2005-04-28 | — | — | US | disclosed |
| US-6867207-B2 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-15 | — | — | US | disclosed |
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2004-08-26 | — | — | US | disclosed |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | LACRAMPE JEAN FERNAND ARMAND (FR) | 2002-06-13 | — | — | US | disclosed |
| EP-1000040-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002505-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
| EP-0232932-B1 | 5,6-DIHYDRO-2-(SUBSTITUTED PHENYL)-1,2,4-TRIAZINE-3,5(2H,4H)-DIONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-01-02 | — | — | EP | disclosed |
| US-4952570-A | ANTIPROTOZOA AGENTS; COCCIDIOSIS | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-08-28 | — | — | US | disclosed |
| US-4912106-A | 5,6-Dihydro-2-(substituted phenyl)-1,2,4-triazine-3,5,(2H,4H)-diones and their use as protozoa combating agents | JANSSEN PHARMACEUTICA N. V. FRAME-319 (BE) | 1990-03-27 | — | — | US | disclosed |
| US-4767760-A | Anti-protozoal 5,6-dihydro-2-(substituted phenyl)-1,2,4-triazine-3,5(2H,4H)-dione derivatives, compositions, and method of use therefor | JANSSEN PHARMACUETICA N.V. (BE) | 1988-08-30 | — | — | US | disclosed |
| EP-0232932-A1 | 5,6-Dihydro-2-(substituted phenyl)-1,2,4-triazine-3,5(2H,4H)-diones | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | IL6ST, CXCR5, ALOX5 | MEN1 4239/4885NR1I2 203/4885KMT2A 4336/4885 |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | CXCR5, HCAR3, IL6ST | MEN1 3111/4885NR1I2 211/4885KMT2A 4590/4885 |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | IL6ST, ALOX5, IL5 | MEN1 4683/4885NR1I2 266/4885KMT2A 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.